Valentina Coronado A

Radiation Oncology Resident at UMNG - INC 🇨🇴 PGY4

[Valentina Coronado A @abcorva21]

@holafly_com pésimo servic, cero recomendado, viaje a España, compré una e sim, x 45 días, nunca me activaron la e sim, servicio al cliente y soporte técnico, ninguna de las soluciones ofrecidas y ajustes hizo q funcionara, me cobraron 2. Veces, llego más de 6 hr sin solución

[Valentina Coronado A @abcorva21]

La peor aerolínea del mundo @Iberia si tienen la oportunidad NUNCA VIAJEN con ellos, pésimos en gestión de asistencia, atención de pqrs, nunca solucionan nada y lo único que hacen es cobrar sumas desorbitantes, sale mejor pagar un nuevo tiquete

Pésimo cero recomendado

[Piet Ost @piet_ost]

What a beautiful message at the end of @Mat_Guc presidency at #ESTRO26 passing the torch to @BarbaraJereczek! See you at #ESTRO27 in Milano, 21-25th of May 2027.

[Instituto Nacional de Cancerología @INCancerologia]

El @incancerología fue oficializado como Centro Ancla del Organismo Internacional de Energía Atómica en la iniciativa Rays of Hope.
Para el doctor Rafael Mariano Grossi director general del OIEA, el INC es “un modelo viable y replicable para países con sistemas de salud más pequeños o con mayores desafíos”.
Más cooperación, más formación, más acceso a atención oncológica de calidad en la región.

[Dr Rishabh Jain @DrRishabhOnco]

🚨 Resectable Gastric Cancer | #GI26

CRITICS-II answers a key question
What is the best preoperative strategy when adjuvant therapy is omitted?

🧪 Trial design
Three fully neoadjuvant approaches compared
➡️ Chemotherapy alone
➡️ Chemotherapy → Chemoradiotherapy
➡️ Chemoradiotherapy alone

🎯 Primary endpoint
1-year event-free survival
Activity threshold ≥75%

📊 Key results
✅ CT → CRT: 1-yr EFS 84% | 1-yr OS 89% | pCR 20%
✅ CRT alone: 1-yr EFS 78% | better compliance | lower toxicity
❌ CT alone: 1-yr EFS 68% | lowest survival | higher toxicity

🧠 Clinical interpretation
• Chemotherapy alone fails efficacy threshold
• Total neoadjuvant therapy gives the best oncologic signal
• CRT alone offers a toxicity-compliant alternative
• CT → CRT emerges as the preferred backbone for phase III testing and organ-sparing strategies

📌 Take-home message
In resectable gastric cancer, treatment intensification before surgery matters.
Pure chemo upfront is no longer convincing.

#OncoTwitter #MedTwitter #GastricCancer #GI26
@asco @oncoalert @Larvol

[Valentina Coronado A @abcorva21]

Its a Great honor to know @DrSpratticus uro love ☢️🩵

[Oscar Tahuahua @OscarTahuahua]

Postmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline-2025

PMRT in ≥4 LN+, T4, residual ypN+; consider in cN1→ypN0 or T3N0; omit in T1-2N0 low-risk.

Hypofractionation is SoC, IMRT & DIBH↓ cardiopulmonary toxicity.
https://t.co/bymMnapHMt @OncoAlert

[Gustavo @gusviani]

Chemo or Not? RT Alone Holds Strong After Hysterectomy 🚨 @OncoAlert

🎯 316 pts, stage IB–IIA, randomized RT vs CRT (NRG/GOG-263)
📊 3y RFS: 88.5% (CRT) vs 85.4% (RT) → NS
📊 OS trend favoring CRT, but no significance
⚠️ Toxicity: 43% vs 15% (CRT ↑)
✅ RT alone highly effective, esp. with IMRT.

👉 Take-home: More toxicity, no clear survival gain. Precision selection needed

See more in https://t.co/tWN3GNyalZ

[Gustavo @gusviani]

🔥 PCS-9: SBRT + ENZA Doubles Disease Control in Oligometastatic CRPC @OncoAlert @dr_cury

🎯 Objective
• Evaluate whether adding SBRT to ADT + enzalutamide ⬆️ outcomes in oligometastatic CRPC (≤5 mets)

🏥 Methods
• Ph 2, randomized, 13 Canadian centers.
• 100 men with oligometastatic CRPC
• Arm A: ADT + ENZA;
Arm B: ADT + ENZA + SBRT
• SBRT: 24–60 Gy in 2–8 fractions to all metastatic sites

📊 Results
• Median rPFS: 4.6 vs 2.3 y (HR 0.48; p=0.014)
• Time to next systemic therapy: 5.1 vs 2.9 y
• No grade 4/5 events; toxicity comparable

➡️ SBRT + ENZA marks a paradigm shift in oligometastatic CRPC management

[Gustavo @gusviani]

🧠 Pre-Op FSRT vs Post-Op FSRT – New Data on Brain Met Resections! @OncoAlert

🎯 Objective
Test if pre-op FSRT improves outcomes vs post-op FSRT in resected brain mets.

🏥 Methods
•458 pts / 534 mets
•27 Gy/3 fx or 30 Gy/5 fx
•LINAC/GK, 2–3 mm margins

📊 Results
•Composite endpoint (LF, nMD, ≥G2 RN):
• Pre-op: 12%
• Post-op: 20% (p=0.018)
•nMD: 1.7% vs 4.7%
•No OS difference

👉 Pre-op FSRT = less meningeal disease & toxicity.

[Mustafa Özdoğan, MD @ozdogan_md]

📢 A new era in head & neck cancer care begins.

#FDA approves #pembrolizumab as the first immunotherapy for perioperative use in resectable LA-HNSCC.

Neoadjuvant + adjuvant strategy now reshapes standard of care.

👇See the full breakdown:

📊 #KEYNOTE689 | �� June 12, 2025

#HeadAndNeckCancer #Immunotherapy #ASCO25 #Oncology #HNSCC #CancerResearch #ASCO #CancerTwitter @ASCO #Oncology

[Goutham Sunny @medoncodoc]

Ultimate review on Reirradiation. All that you need to know in one place. Must read!!

https://t.co/CJJhTCmYtI
@OncoAlert

[Yakup Ergün @dr_yakupergun]

Axillary Management After Neoadjuvant Systemic Therapy

From Dr. Mediget Teshome's wonderful presentation👇
#ASCO25

[Krishan Jethwa @KrishanJethwa]

🚨ESOPEC, Patterns of Recurrence🚨

🔥DM is the predominant pattern of recurrence and a large driver of mortality (~30-50%)
⚠️Locoregional Recurrence Remains notable (~20%)

🧐 Wonder about combined (Chemo + CRT) 🧨 to build on D-FLOT or FLOT, ❓ with organ preservation

#ASCO25

[Mustafa Özdoğan, MD @ozdogan_md]

🚨 Exercise is no longer optional, it is essential!

One of the most impactful studies at #ASCO25

🏃‍♂️ The #CHALLENGE trial (LBA4319) proves that structured exercise after chemo in stage III colon cancer is not just lifestyle—it’s life-saving.

📊 5y DFS: 80.3% vs 73.9%
❤️ 8y OS: 90.3% vs 83.2%
📉 Mortality risk ↓ by 37%

📄 Simultaneously in @NEJM https://t.co/y4e9u71OLI

#ColorectalCancer #OncoTwitter #ExerciseOncology #exercise

[Piet Ost @piet_ost]

📢 STORM trial breaking results at #ESTRO25!

🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa.

🧬 ENRT+MDT:
✅ Superior bRFS (57% vs 41%, p=0.014)
✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006)
✅ Superior MFS (76% vs 63%, p=0.06)
❌ No increase in ≥G2 GU/GI toxicity

[Gustavo @gusviani]

HDR vs LDR Boost in Prostate Cancer: Is One Better? @OncoAlert
New RCT sheds light on long-term efficacy for unfavorable-risk prostate cancer
🎯 Objective
Compare HDR vs LDR brachytherapy boost + EBRT in terms of biochemical control
🏥 Methods
•190 👥 randomized: HDR (15 Gy pre-EBRT) vs LDR (110 Gy post-EBRT)
•All received pelvic EBRT (46 Gy/23 fx) via IMRT/VMAT or 3D-CRT
•76% received ADT; median f/u 74 months
•PSA ≤0.2 ng/ml at 4y = cure
📊 Key Results
•4y PSA ≤0.2: HDR 81% | LDR 83%
•8y bPFS: HDR 85% | LDR 84%
•OS/CSS similar
🔛Takeway: Both techniques offer durable efficacy. Use may depend on center expertise &👥 factors🤝

[Gustavo @gusviani]

Meningioma Grading Will Never Be the Same: 🔑 Takeaways from cIMPACT-NOW Update 8 @OncoAlert
For oncologists & radiation oncologists: here’s what you need to know about the molecular era of meningiomas🧵(1/14)

[Valentina Coronado A @abcorva21]

@SectorMovilidad @BogotaTransito @Bogota @ClaudiaDiazAco1 Ciclovía nocturna en la calle 26 depsues de protestas manifestaciones cierres de vías Transmilenio y se les ocurre q la mejor idea es continuar con el cierre de la 26 para la Ciclovía nocturna con este caos vehicular, pésima logística.